Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 Spike Trimer (N501Y, D614G), His Tag (MALS verified), 50µg  

Recombinant SARS-CoV-2 Spike Trimer (N501Y, D614G), His Tag (MALS verified), 50µg

Recombinant SARS-CoV-2 Spike Trimer (N501Y, D614G), AA Val 16 - Pro 1213, expressed from human 293 cells (HEK293), His Tag (MALS verified)

Synonyms: Recombinant, Spike, S protein, Spike glycoprotein, S glycoprotein

More details

SPN-C52Hp-50

Availability: within 10-14 days

585,00 €

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 S protein (N501Y,D614G), His Tag (SPN-C52Hp) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1(N501Y, D614G)). The N501Y/D614G mutations were identified in multiple SARS-CoV-2 variants which emerged in the United Kingdom (known as B.1.1.7, 20B/501Y.V1 or VOC 202012/01), South Africa(known as B.1.351 or 20C/501Y.V2), and Brazil (Known as P.1). Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 138.0 kDa. The protein migrates as 170-220 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by reduced SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2"
Maeda, Toyoda, Kuwata et al
Int J Mol Sci (2024) 25 (2)
(2) "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2"
Maeda, Toyoda, Kuwata et al
Int J Mol Sci (2024) 25 (2)
(3) "Plant stanol consumption increases anti-COVID-19 antibody responses, independent of changes in serum cholesterol concentrations: a randomized controlled trial"
van Brakel, Mensink, Lütjohann et al
Am J Clin Nutr (2024)
Showing 1-3 of 35403 papers.